» Articles » PMID: 37205763

Structure of the Immunoregulatory Sialidase NEU1

Overview
Journal Sci Adv
Specialties Biology
Science
Date 2023 May 19
PMID 37205763
Authors
Affiliations
Soon will be listed here.
Abstract

Sialic acids linked to glycoproteins and glycolipids are important mediators of cell and protein recognition events. These sugar residues are removed by neuraminidases (sialidases). Neuraminidase-1 (sialidase-1 or NEU1) is a ubiquitously expressed mammalian sialidase located in lysosomes and on the cell membrane. Because of its modulation of multiple signaling processes, it is a potential therapeutic target for cancers and immune disorders. Genetic defects in NEU1 or in its protective protein cathepsin A (PPCA, CTSA) cause the lysosomal storage diseases sialidosis and galactosialidosis. To further our understanding of this enzyme's function at the molecular level, we determined the three-dimensional structure of murine NEU1. The enzyme oligomerizes through two self-association interfaces and displays a wide substrate-binding cavity. A catalytic loop adopts an inactive conformation. We propose a mechanism of activation involving a conformational change in this loop upon binding to its protective protein. These findings may facilitate the development of selective inhibitor and agonist therapies.

Citing Articles

Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation.

Lin J, Li Y, Chen B, Su H, Zeng Y, Zeng R Ann Clin Transl Neurol. 2024; 11(11):2998-3009.

PMID: 39482827 PMC: 11572746. DOI: 10.1002/acn3.52212.


Causal associations of MICB, CTSA, and MMP9 proteins with oral cancer: Mendelian randomization study.

Dong B, Hua J, Ma S, Wang L, Xiao H, Qiao X Sci Rep. 2024; 14(1):25645.

PMID: 39465349 PMC: 11514235. DOI: 10.1038/s41598-024-77042-0.


Neuraminidase-1 (NEU1): Biological Roles and Therapeutic Relevance in Human Disease.

Du J, Shui H, Chen R, Dong Y, Xiao C, Hu Y Curr Issues Mol Biol. 2024; 46(8):8031-8052.

PMID: 39194692 PMC: 11353077. DOI: 10.3390/cimb46080475.


The role of platelet desialylation as a biomarker in primary immune thrombocytopenia: mechanisms and therapeutic perspectives.

Zhang Q, Huang M, Thomas E, Wang L, Liu J, Li X Front Immunol. 2024; 15:1409461.

PMID: 38979425 PMC: 11228137. DOI: 10.3389/fimmu.2024.1409461.


Clinical and Structural Characteristics of NEU1 Variants Causing Sialidosis Type 1.

Li Y, Liu Y, Wang R, Ao R, Xiang F, Zhang X J Mov Disord. 2024; 17(3):282-293.

PMID: 38600684 PMC: 11300387. DOI: 10.14802/jmd.23145.


References
1.
Wang D, Bonten E, Yogalingam G, Mann L, dAzzo A . Short-term, high dose enzyme replacement therapy in sialidosis mice. Mol Genet Metab. 2005; 85(3):181-9. DOI: 10.1016/j.ymgme.2005.03.007. View

2.
Watts A, Damager I, Amaya M, Buschiazzo A, Alzari P, Frasch A . Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: tyrosine is the catalytic nucleophile. J Am Chem Soc. 2003; 125(25):7532-3. DOI: 10.1021/ja0344967. View

3.
Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O . Highly accurate protein structure prediction with AlphaFold. Nature. 2021; 596(7873):583-589. PMC: 8371605. DOI: 10.1038/s41586-021-03819-2. View

4.
Zhou X, Zhai Y, Liu C, Yang G, Guo J, Li G . Sialidase NEU1 suppresses progression of human bladder cancer cells by inhibiting fibronectin-integrin α5β1 interaction and Akt signaling pathway. Cell Commun Signal. 2020; 18(1):44. PMC: 7066847. DOI: 10.1186/s12964-019-0500-x. View

5.
Uemura T, Shiozaki K, Yamaguchi K, Miyazaki S, Satomi S, Kato K . Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene. 2009; 28(9):1218-29. DOI: 10.1038/onc.2008.471. View